Search results
Showing 271 to 285 of 2548 results for methods
In development Reference number: GID-TA10227 Expected publication date: TBC
In development Reference number: GID-TA10446 Expected publication date: TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340
In development Reference number: GID-TA10313 Expected publication date: TBC
In development Reference number: GID-TA10326 Expected publication date: TBC
Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia .
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development Reference number: GID-TA10573 Expected publication date: TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
In development Reference number: GID-TA10623 Expected publication date: TBC
Evidence-based recommendations on ixazomib with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Bortezomib monotherapy for relapsed multiple myeloma (TA129)
Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.
NICE has developed a medtech innovation briefing (MIB) on CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease .
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Awaiting development Reference number: GID-TA10774 Expected publication date: TBC
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Awaiting development Reference number: GID-TA10682 Expected publication date: TBC
In development Reference number: GID-TA10311 Expected publication date: TBC